Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants


Feasibility, Acceptability and Safety of pre-exposure prophylaxis during Pregnancy and Breast Feeding to establish drug thresholds for optimal adherence when FTC/TDF is administered daily under direct observation during pregnancy and in the postpartum period.

Primary Objectives

  • To characterize PrEP adherence among HIV-uninfected adolescent and young adult women (aged 16-24 years) who initiate once-daily emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) in pregnancy and are followed through 6 months postpartum, when offered adherence support through mobile technology and drug level-directed counseling.
  • To compare maternal and infant adverse events (including pregnancy outcomes) between women who initiate PrEP and women who decline PrEP over the observation period.


  • Dr Elizea Horne (Principal Investigator)
  • Dr Faeezah Patel (Sub-Investigator)
  • Dr Mrinmayee Dhar (Sub-Investigator)
  • Muneerah Khan (Sub-Investigator)
  • Jeanne Coetzee (Sub-Investigator)
  • Tiffany Seef (Clinical Associate)
  • Othusitse Segalo (Clinical Associate)

Latest Update:

March 2024

For more about IMPAACT 2009 please email


Research and Policy Briefs

Project Brief: IMPAACT 2009

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.